Approximately 100,000 people in the U.S. will be diagnosed with melanoma this year, according to the American Cancer Society.

Scientists have pinpointed thousands of genetic changes in a gene that may increase a person's risk of developing breast and ...

The MEDIOLA trial evaluated olaparib (Lynparza) and durvalumab (Imfinzi) with or without bevacizumab in recurrent ovarian cancer and showed a 34% response rate with the PARP inhibitor and the PD-L1 ...

Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free ...

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

If you have any concerns, please consult your physician. Ovarian cancer is the most lethal gynecological malignancy. It is often called a “silent killer” because its symptoms are non-specific ...

Within astrology, Cancer is a water sign represented by the crab. What is the Cancer personality like? Cancers contain multitudes if you're patient enough to let them open up — or if they like ...

NEW YORK – Researchers are planning larger follow-up studies of AstraZeneca's Lynparza (olaparib) in biomarker-selected subgroups after a Phase II trial showed the PARP inhibitor was effective in ...

A mini-oral presentation at ESMO will highlight first results from the endometrial and ovarian cancer cohorts of the TROPION-PanTumor03 Phase II trial of datopotamab deruxtecan. Several presentations ...

A University of Alberta research team has found a potential new treatment target for ovarian cancer. Their new research is the first to comprehensively investigate the elevated expression of a ...

NEW YORK (WABC) -- Eyewitness News is celebrating a special homecoming on Tuesday as our friend and colleague Stacey Sager returns after her latest cancer ... called Lynparza which aims to stop ...